Related Articles
Prognostic significance of sirtuin 2 protein nuclear localization in glioma: An immunohistochemical study
Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab
Achievement of three year remission in a case of aggressive glioblastoma using a multidisciplinary treatment strategy: A case report
Clinical outcomes in primary scalp angiosarcoma Corrigendum in /10.3892/ol.2020.12025
Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide